Merck & Company

MRK-N

NYSE:MRK

76.37
0.18 (0.24%)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.
More at Wikipedia

Analysis and Opinions about MRK-N

Signal
Opinion
Expert
TOP PICK
TOP PICK
June 10, 2013

Entire healthcare index in the US hit a low at twice Book, which was last seen in 1982. Whole group has been recovering. Currently heading towards 4X BV but it peaked at 10. So he thinks there is room for these stocks to keep on moving. He went through the index to see which one had been left behind and had a decent dividend and chose this one.

Show full opinionHide full opinion

Entire healthcare index in the US hit a low at twice Book, which was last seen in 1982. Whole group has been recovering. Currently heading towards 4X BV but it peaked at 10. So he thinks there is room for these stocks to keep on moving. He went through the index to see which one had been left behind and had a decent dividend and chose this one.

COMMENT
COMMENT
June 7, 2013

As a general view, he feels there are some good opportunities in the healthcare space. His office owns Pfizer (PFE-N) instead. Bad news in healthcare is behind it. With the aging population, this sector would be a good area to be invested in for the long-term. 3.5% dividend yield.

Show full opinionHide full opinion

As a general view, he feels there are some good opportunities in the healthcare space. His office owns Pfizer (PFE-N) instead. Bad news in healthcare is behind it. With the aging population, this sector would be a good area to be invested in for the long-term. 3.5% dividend yield.

TOP PICK
TOP PICK
June 4, 2013

Pharmaceutical sector was way out of favour for 12-13 years. Recently, what made it unattractive has made it very attractive. Have predictable cash flows. Paying out about 50% of their earnings, (3.46% dividend yield) and this could go higher. Have recently been having good success in science.

Show full opinionHide full opinion

Pharmaceutical sector was way out of favour for 12-13 years. Recently, what made it unattractive has made it very attractive. Have predictable cash flows. Paying out about 50% of their earnings, (3.46% dividend yield) and this could go higher. Have recently been having good success in science.

TOP PICK
TOP PICK
April 9, 2013

Pharma is one of the strongest performing groups after many years of underperforming. This company has an earnings yield of just over 8%. A US treasury bond yield is at 1.7%. The market has assessed the risk of default of this company as being less than a U.S. Treasury bond. There will probably be 8%-9% cash flow growth over the next 5 years. Dividend yield of 3.76%.

Show full opinionHide full opinion

Pharma is one of the strongest performing groups after many years of underperforming. This company has an earnings yield of just over 8%. A US treasury bond yield is at 1.7%. The market has assessed the risk of default of this company as being less than a U.S. Treasury bond. There will probably be 8%-9% cash flow growth over the next 5 years. Dividend yield of 3.76%.

DON'T BUY
DON'T BUY
March 27, 2013

Probably has a little better pipeline coming then Pfizer (PFE-N), so may be a little bit better growth. Still very modest growth for a great company but not cheap enough to buy it here when you can get companies with good yields and good growth at reasonable prices.

Show full opinionHide full opinion
Merck & Company (MRK-N)
March 27, 2013

Probably has a little better pipeline coming then Pfizer (PFE-N), so may be a little bit better growth. Still very modest growth for a great company but not cheap enough to buy it here when you can get companies with good yields and good growth at reasonable prices.

BUY
BUY
March 15, 2013

(Market Call Minute.) Likes the group in general.

Show full opinionHide full opinion
Merck & Company (MRK-N)
March 15, 2013

(Market Call Minute.) Likes the group in general.

DON'T BUY
DON'T BUY
January 14, 2013

Pharma have been one of the best performing sectors last year. Good focus. Going forward, their issue is the large drugs going off patent. He does not see the potential going forward. He prefers diagnostics or nutritionals.

Show full opinionHide full opinion
Merck & Company (MRK-N)
January 14, 2013

Pharma have been one of the best performing sectors last year. Good focus. Going forward, their issue is the large drugs going off patent. He does not see the potential going forward. He prefers diagnostics or nutritionals.

BUY
BUY
November 26, 2012

(Market Cal Minute) $57.78, 51% upside.

Show full opinionHide full opinion
Merck & Company (MRK-N)
November 26, 2012

(Market Cal Minute) $57.78, 51% upside.

HOLD
HOLD
November 12, 2012

Had a whole lot of problems with patent expiration. Now they have had their big patent expirations out of the way. Doesn’t know what is going to happen in the next couple of months.

Show full opinionHide full opinion
Merck & Company (MRK-N)
November 12, 2012

Had a whole lot of problems with patent expiration. Now they have had their big patent expirations out of the way. Doesn’t know what is going to happen in the next couple of months.

BUY
BUY
November 7, 2012

(Market Call Minute.) Ranks very well. Nice and safe dividend of 3.8%.

Show full opinionHide full opinion
Merck & Company (MRK-N)
November 7, 2012

(Market Call Minute.) Ranks very well. Nice and safe dividend of 3.8%.

DON'T BUY
DON'T BUY
October 23, 2012

Trading at about 12X earnings which is not really expensive. Has over 3% dividend. The problem is that most people don’t expect the earnings to grow and are actually going to decline over the next few years. Would prefer Abbot Labs (ABT-N) or Teva Pharmaceuticals (TEVA-N).

Show full opinionHide full opinion
Merck & Company (MRK-N)
October 23, 2012

Trading at about 12X earnings which is not really expensive. Has over 3% dividend. The problem is that most people don’t expect the earnings to grow and are actually going to decline over the next few years. Would prefer Abbot Labs (ABT-N) or Teva Pharmaceuticals (TEVA-N).

HOLD
HOLD
October 5, 2012

Chart shows a long, long sideways market followed by an outstanding pop. Chart is showing a parabolic move but the trend is up. Typically when a stock moves quite a bit off a trend line, be prepared that it could return to the trend line. If you are a longer-term investor, stay with the story as long as it doesn’t break the trend line.

Show full opinionHide full opinion
Merck & Company (MRK-N)
October 5, 2012

Chart shows a long, long sideways market followed by an outstanding pop. Chart is showing a parabolic move but the trend is up. Typically when a stock moves quite a bit off a trend line, be prepared that it could return to the trend line. If you are a longer-term investor, stay with the story as long as it doesn’t break the trend line.

COMMENT
COMMENT
September 12, 2012

US health care valuations are very, very attractive. They have reasonable PE’s and good dividends. This is all about the 3.8% dividend. He would prefer something with a cheaper valuation and better dividend growth.

Show full opinionHide full opinion
Merck & Company (MRK-N)
September 12, 2012

US health care valuations are very, very attractive. They have reasonable PE’s and good dividends. This is all about the 3.8% dividend. He would prefer something with a cheaper valuation and better dividend growth.

COMMENT
COMMENT
April 19, 2012
On a seasonal pattern, healthcare stocks should do well coming into the summer months. This one has kind of marked time for a few months. Nice dividend at 4.3%. (See Top Picks.)
Show full opinionHide full opinion
Merck & Company (MRK-N)
April 19, 2012
On a seasonal pattern, healthcare stocks should do well coming into the summer months. This one has kind of marked time for a few months. Nice dividend at 4.3%. (See Top Picks.)
WEAK BUY
WEAK BUY
March 27, 2012
Likes the group, nice dividends. They trade at a discount. There are concerns about generic competition and blockbuster drugs coming off patients. But he sees that as built into the price and MRK is attractive to invest in. He has preferred some other companies in the space over MRK.
Show full opinionHide full opinion
Merck & Company (MRK-N)
March 27, 2012
Likes the group, nice dividends. They trade at a discount. There are concerns about generic competition and blockbuster drugs coming off patients. But he sees that as built into the price and MRK is attractive to invest in. He has preferred some other companies in the space over MRK.
Showing 61 to 75 of 188 entries